.jpg "uniQure NV (NASDAQ: QURE)")
In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on uniQure NV (QURE), with a price target of $73.00. The company’s shares closed last Monday at $42.91.
According to TipRanks.com, Chattopadhyay has 0 stars on 0-5 star ranking scale with an average return of -11.7% and a 32.2% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences Inc, and Voyager Therapeutics Inc.
Currently, the analyst consensus on uniQure NV is a Strong Buy with an average price target of $91.00, an 110.7% upside from current levels. In a report issued on October 11, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $79.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $82.49 and a one-year low of $21.98. Currently, uniQure NV has an average volume of 572.3K.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of QURE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
